These findings identify a new therapeutic opportunity for CTX and potentially other EGFR-targeted antibodies in PaCa, whereby it may be repurposed as a targeted drug delivery platform. The gene discussed is EGFR; the disease is permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome.